Mok et al. revealed no evident change in serum IL-33 between the control group and SLE patients but showed significantly elevated ST2, a marker that was linked to SLE disease activity and severity, demonstrating that ST2 may be a surrogate marker of disease activity [24]. This evidence concerns the gene IL33 and systemic lupus erythematosus.